How Much More Efficient Are Adaptive Platform Trials Than Multiple Stand-Alone Trials? A Comprehensive Simulation...

Area of Science:

• Clinical Trials Methodology
• Drug Development
• Epidemiology

Background:

• The COVID-19 pandemic increased interest in adaptive platform clinical trials (APTs).
• APTs compare multiple drugs against a common control group, allowing for drug additions/exclusions during the trial.
• The comparative efficiency of APTs versus multiple stand-alone trials remains under-explored.

Purpose of the Study:

• To simulate and compare the efficiency of APTs and multiple stand-alone trials for COVID-19 drug development.
• To evaluate total development period, sample size, and statistical operating characteristics.
• To identify factors influencing APT efficiency.

Main Methods:

• Simulation studies were conducted for drug development in hospitalized COVID-19 patients.
• Scenarios evaluated APTs with and without staggered drug addition.
• Key metrics included total development period, total sample size, and statistical operating characteristics.

Main Results:

• APTs without staggered drug addition showed shorter development periods than stand-alone trials, but this advantage decreased with accelerated enrollment.
• APTs with staggered drug addition could reduce development time in some cases.
• Efficiency gains varied based on enrollment speed, sample size, error rate adjustments, allocation ratios, and drug addition intervals.

Conclusions:

• APTs can enhance efficiency (total development period, sample size) over stand-alone trials without compromising statistical validity.
• The degree of improvement is contingent upon several dynamic trial parameters.
• Careful planning and consideration of APT complexity are crucial, especially during pandemics.